Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

16:08
10/09/16
10/09
16:08
10/09/16
16:08

Merck reports 18-month data from KEYNOTE-010, other Keytruda data sets

Merck announced that Keytruda demonstrated superiority in overall survival at 18 months compared to standard of care chemotherapy -- docetaxel -- in patients with metastatic non-small cell lung cancer previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1, as well as patients with high levels of PD-L1 expression. The data, from the phase 2/3 KEYNOTE-010 trial, will be presented at the ESMO 2016 Congress. In addition, an analysis of patient-reported health-related quality of life outcomes showed more patients treated with Keytruda reported positive outcomes compared to patients treated with chemotherapy. Separately, researchers also presented an analysis of PD-L1 prevalence across three separate studies, including KEYNOTE-010. Overall, 66 percent of patients with metastatic NSCLC expressed any level of PD-L1, and 28 percent expressed high levels of PD-L1. Specifically, the new data from KEYNOTE-010 included six months of additional follow-up, with a median follow-up of 19.2 months, and showed superior outcomes of OS, PFS, and ORR with Keytruda compared to docetaxel in patients with PD-L1 expression as well as high levels of PD-L1 expression -- with consistency of outcomes across Keytruda doses. In patients with PD-L1 expression, OS at 18 months was 37 percent with Keytruda 2 mg/kg, 43 percent with Keytruda 10 mg/kg, and 24 percent with docetaxel. Among all patients, median OS was 10.5 months with Keytruda 2 mg/kg, 13.6 months with Keytruda 10 mg/kg, and 8.6 months with docetaxel. ORR was 19 percent with Keytruda 2 mg/kg, 20 percent with Keytruda 10 mg/kg and 10 percent with docetaxel. Responses to Keytruda continued to be durable; among patients with any level of PD-L1 expression who responded to treatment, 60 percent on each of the Keytruda treatment arms were alive, progression-free, and had not received additional therapy for their disease, compared to 15 percent in the docetaxel treatment arm. In patients with high levels of PD-L1 expression, OS at 18 months was 46 percent with Keytruda 2 mg/kg, 52 percent with Keytruda 10 mg/kg, and 24 percent with docetaxel. In this group, median OS was 15.8 months with Keytruda 2 mg/kg, 18.8 months with Keytruda 10 mg/kg, and 8.2 months with docetaxel. ORR was 29 percent with Keytruda 2 mg/kg, 32 percent with Keytruda 10 mg/kg, and nine percent with docetaxel. Responses to Keytruda continued to be durable; among patients with high levels of PD-L1 expression who responded to treatment, 68 and 63 percent on the Keytruda 2 mg/kg and 10 mg/kg treatment arms, respectively, were alive, progression-free, and had not received additional therapy for their disease, compared to 15 percent in the docetaxel treatment arm. Treatment-related adverse events remained lower with Keytruda compared to docetaxel. Also reported at the ESMO 2016 Congress were health-related quality of life outcomes from the KEYNOTE-010 trial. Overall, from baseline to the 12-week assessment, patients treated with Keytruda reported numeric improvements, some of which were significant, in HRQoL and prolonged time to deterioration of lung cancer symptoms compared with docetaxel. Additionally, results from a third NSCLC abstract at the ESMO 2016 Congress explored, for the first time, the prevalence of PD-L1 in patients screened across multiple studies. The analysis assessed 4,784 patients with NSCLC who had tumors evaluable for PD-L1 expression and were screened for eligibility in three registrational studies of Keytruda -- KEYNOTE-001, KEYNOTE-010, and KEYNOTE-024. Based on this pooled analysis, 66 percent of patients across all three trials were determined to express PD-L1 and 28 percent were determined to have high levels of PD-L1 expression. These findings were similar across demographic and disease characteristics examined, including prior lines of therapy, age, tumor source, and histology.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

02:45
01/23/18
01/23
02:45
01/23/18
02:45
General news
FX Update: The dollar gained on the Senate vote »

FX Update: The dollar…

02:25
01/23/18
01/23
02:25
01/23/18
02:25
General news
BoJ's Kuroda sounded dovish at his post-meeting press conference »

BoJ's Kuroda sounded…

CENT

Central Garden & Pet

$37.82

0.09 (0.24%)

20:37
01/22/18
01/22
20:37
01/22/18
20:37
Upgrade
Central Garden & Pet rating change at KeyBanc »

Central Garden & Pet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPAR

Inter Parfums

$45.90

-1.9 (-3.97%)

20:33
01/22/18
01/22
20:33
01/22/18
20:33
Downgrade
Inter Parfums rating change at KeyBanc »

Inter Parfums downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

, PG

Procter & Gamble

$91.89

0.82 (0.90%)

20:25
01/22/18
01/22
20:25
01/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

PG

Procter & Gamble

$91.89

0.82 (0.90%)

VZ

Verizon

$53.46

1.55 (2.99%)

KMB

Kimberly-Clark

$116.91

1.42 (1.23%)

TRV

Travelers

$139.35

1.5 (1.09%)

FITB

Fifth Third

$32.77

0.27 (0.83%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

WAT

Waters

$214.77

4.05 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 06

    Feb

  • 13

    Feb

  • 16

    Feb

  • 08

    Mar

SSNLF

Samsung

19:26
01/22/18
01/22
19:26
01/22/18
19:26
Hot Stocks
Samsung says new tariff 'great loss' for American consumers, workers »

In reaction to a final…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

FTK

Flotek

$5.71

0.07 (1.24%)

19:23
01/22/18
01/22
19:23
01/22/18
19:23
Hot Stocks
Flotek expands lines of chemistry technologies »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ACLS

Axcelis

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Upgrade
Axcelis rating change at Stifel »

Axcelis upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$90.64

2.8 (3.19%)

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Downgrade
Wayfair rating change at Stifel »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EPE

EP Energy

$2.48

0.17 (7.36%)

19:00
01/22/18
01/22
19:00
01/22/18
19:00
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BRSS

Global Brass and Copper

$33.30

-0.55 (-1.62%)

18:47
01/22/18
01/22
18:47
01/22/18
18:47
Hot Stocks
Global Brass and Copper reports oil spill at Somers Thin Strip plant »

Somers Thin Strip, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, DIS

Disney

$111.10

0.51 (0.46%)

18:38
01/22/18
01/22
18:38
01/22/18
18:38
Hot Stocks
Netflix doesn't see Disney-Fox deal as a direct threat »

Says Disney (DIS) and Fox…

NFLX

Netflix

$227.58

7.12 (3.23%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

T

AT&T

$37.87

0.66 (1.77%)

, TWX

Time Warner

$94.00

0.64 (0.69%)

18:37
01/22/18
01/22
18:37
01/22/18
18:37
Periodicals
Judge orders DOJ to seek consent to give data to AT&T, Time Warner, Reuters says »

Judge Richard Leon, who…

T

AT&T

$37.87

0.66 (1.77%)

TWX

Time Warner

$94.00

0.64 (0.69%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

VIA

Viacom

$39.30

0.1 (0.26%)

VIAB

Viacom

$33.94

0.58 (1.74%)

DISCA

Discovery

$26.33

0.62 (2.41%)

SNI

Scripps Networks

$88.77

0.27 (0.31%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

CMCSK

Comcast

CHTR

Charter

$370.25

4.2 (1.15%)

ATUS

Altice USA

$21.90

0.6 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 27

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

18:25
01/22/18
01/22
18:25
01/22/18
18:25
Hot Stocks
Netflix says it has a ways to go to hit 60M U.S. subscribers »

Says has a ways to go to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

BIVV

Bioverativ

$103.79

39.68 (61.89%)

, SNY

Sanofi

$43.20

-1.4 (-3.14%)

18:15
01/22/18
01/22
18:15
01/22/18
18:15
Downgrade
Bioverativ, Sanofi rating change at Jefferies »

Bioverativ downgraded to…

BIVV

Bioverativ

$103.79

39.68 (61.89%)

SNY

Sanofi

$43.20

-1.4 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

ECR

Eclipse Resources

$2.33

0.05 (2.19%)

18:12
01/22/18
01/22
18:12
01/22/18
18:12
Conference/Events
Eclipse Resources to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

18:10
01/22/18
01/22
18:10
01/22/18
18:10
Hot Stocks
Netflix says Asia market projects 'well' »

Says very pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:06
01/22/18
01/22
18:06
01/22/18
18:06
Hot Stocks
Steel Dynamics CEO says domestic inventory levels moderated »

Steel Dynamics CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:04
01/22/18
01/22
18:04
01/22/18
18:04
Earnings
Steel Dynamics reports Q4 EPS 54c excluding items, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

IMI

Intermolecular

$1.61

0.14 (9.52%)

18:02
01/22/18
01/22
18:02
01/22/18
18:02
Hot Stocks
Intermolecular and SITRI expand alliance to address Chinese market »

Intermolecular and SITRI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

, CHL

China Mobile

$51.97

0.45 (0.87%)

18:01
01/22/18
01/22
18:01
01/22/18
18:01
Hot Stocks
EXFO partners with China Mobile to prepare network for IoT »

EXFO Inc. (EXFO)…

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

CHL

China Mobile

$51.97

0.45 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$111.12

-1.84 (-1.63%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SFNC

Simmons First National

$59.50

0.35 (0.59%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Earnings
Simmons First National reports Q4 core EPS 97c, consensus 88c »

Reports Q4 core net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

, SSNLF

Samsung

17:59
01/22/18
01/22
17:59
01/22/18
17:59
Hot Stocks
Whirlpool chairman praises Trump's move to establish tariff on washing machines »

Whirlpool (WHR) chairman…

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 30

    Jan

AMBC

Ambac Financial

$16.02

0.07 (0.44%)

17:48
01/22/18
01/22
17:48
01/22/18
17:48
Hot Stocks
Ambac Financial announces approval of plan amendment »

Ambac Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.